About
CAR-T Stem Cell Therapy
Areas of Focus
Categories
Stem Cell & Cellular TherapyBoston & New England
Team (5)
Adi Osovsky, S.J.D.
General Counsel
Vor Biopharma
executive
Dallan Murray
Chief Commercial Officer
Vor Biopharma
team_member
Jean-Paul Kress, M.D.
Chief Executive Officer and Chairman
Vor Biopharma
board_chairexecutive
Qing Zuraw
Chief Development Officer
Vor Biopharma
team_member
Sandy Mahatme
Chief Financial Officer, Chief Business Officer
Vor Biopharma
executive
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
115
By Phase
PHASE1/PHASE2: 2
By Status
TERMINATED: 3
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT05984199Lead Sponsor
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
PHASE1/PHASE2Terminated
38 participants
Started: Dec 11, 2023 · Completed: May 28, 2025
NCT05309733Lead Sponsor
A Long-term Follow-up Study of Patients Who Received VOR33
N/ATerminated
10 participants
Started: Apr 15, 2022 · Completed: May 28, 2025
NCT04849910Lead Sponsor
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
PHASE1/PHASE2Terminated
67 participants
Started: Dec 16, 2021 · Completed: May 28, 2025
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...